文献速递肝病

阶梯式远程治疗减少慢性肝病患者不健康饮酒的随机对照试验

A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease.
PubMed 文献 · Hepatology · 2026-06-24

这项随机对照试验在3个医疗系统纳入157例慢性肝病伴不健康饮酒患者,比较远程阶梯式酒精治疗(SAT)与常规护理(UC)。SAT在主要结局(饮酒低于中度水平的比例)上未优于UC,但在第3和第6个月每周饮酒量较基线的减少幅度更大,且6个月效应在多变量模型中仍显著。

要点

  • SAT未改善主要结局:饮酒低于中度水平的比例与UC无差异。
  • SAT在3个月和6个月时每周饮酒量减少均优于UC(p=0.03)。
  • 6个月时SAT组30天戒酒率29% vs UC组18%(p=0.14)。

核心结论

  • SAT在主要结局上未优于UC,但在6个月时较UC更大幅度减少饮酒量,可能对肝病科有价值。

研究设计与样本

  • 随机对照试验,纳入157例慢性肝病伴不健康饮酒患者,来自1个安全网和2个退伍军人事务肝病门诊,2022年3月1日至2024年2月28日入组。
  • SAT组81例接受阶梯治疗(第1步:3次动机性访谈;第2步:3个月无饮酒减少则转诊成瘾医学),UC组76例接受常规护理,在第3和6个月评估。

主要发现

  • SAT与UC在主要结局(饮酒低于中度水平的百分比)上无差异。
  • SAT较UC从基线到第3个月每周饮酒量减少更多(估计值-0.66,p=0.03),到第6个月亦更多(估计值-0.67,p=0.03)。
  • 控制协变量后,SAT对6个月饮酒减少的效应仍显著(p=0.02)。
  • 第6个月30天戒酒率SAT组29%、UC组18%(p=0.14)。
  • 基线减少饮酒动机与治疗反应正相关。

临床怎么用

  • 在肝病科对慢性肝病伴不健康饮酒患者可考虑提供远程阶梯式酒精治疗,以帮助减少饮酒量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Unhealthy alcohol use is prevalent in chronic liver disease (CLD). This randomized controlled trial evaluated the efficacy of telehealth stepped alcohol treatment (SAT) in 3 healthcare systems. APPROACH AND RESULTS: Participants (N=157) with CLD and unhealthy alcohol use (>7 drinks/week or ≥4/day for women; >14/week or ≥5/day for men; or heavy episodic drinking, using timeline followback), were enrolled at a safety-net and 2 Veterans Affairs hepatology clinics from March 1, 2022, to February 28, 2024. Participants were randomized to SAT (N=81; Step 1: three motivational interviewing sessions; Step 2: addiction medicine referral if no drinking reduction at month 3) or usual care (UC; N=76) and were evaluated at months 3 and 6. Alcohol use reduction was analyzed using bivariate tests and multivariable modeling. Baseline characteristics were: median age 61, 86% male, 48% with cirrhosis (37% decompensation), and 78% with alcohol use disorder. Compared with UC, SAT had no difference in percentage of alcohol use below moderate level (primary outcome) but had a greater reduction in drinks/week from baseline to month 3 (estimate -0.66, p =0.03) and month 6 (estimate -0.67, p =0.03) (secondary outcome). The 6-month effect of SAT (vs. UC) on alcohol use reduction remained significant ( p =0.02), controlling for covariates. At month 6, 30-day abstinence rates were 29% for SAT and 18% for UC ( p =0.14). Baseline motivation to reduce alcohol use was positively associated with treatment response. CONCLUSIONS: SAT was not superior on the primary outcome, yet reduced alcohol use more than UC at 6 months in this difficult-to-engage population and may be valuable in hepatology.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Satre DD, Taj L, Wong RJ, et al. A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease. Hepatology. 2026. PMID: 42340251. doi:10.1097/HEP.0000000000001796

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。